Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.

Abstract

Adenosine diphosphate (ADP)-mediated platelet aggregation is signaled through two distinct G protein-coupled receptors (GPCR) on the platelet surface: P2Y12 and P2Y1. Blocking P2Y12 receptor is a clinically well-validated strategy for antithrombotic therapy. P2Y1 antagonists have been shown to have the potential to provide equivalent antithrombotic efficacy as P2Y12 inhibitors with reduced bleeding in preclinical animal models. We have previously reported the discovery of a potent and orally bioavailable P2Y1 antagonist, 1. This paper describes further optimization of 1 by introducing 4-aryl groups at the hydroxylindoline in two series. In the neutral series, 10q was identified with excellent potency and desirable pharmacokinetic (PK) profile. It also demonstrated similar antithrombotic efficacy with less bleeding compared with the known P2Y12 antagonist prasugrel in rabbit efficacy/bleeding models. In the basic series, 20c (BMS-884775) was discovered with an improved PK and liability profile over 1. These results support P2Y1 antagonism as a promising new antiplatelet target.

• Authors: Wu Yang, Yufeng Wang, Amy Lai, Jennifer X Qiao, Tammy C Wang, Ji Hua, Laura A Price, Hong Shen, Xue-qing Chen, Pancras Wong, Earl Crain, Carol Watson, Christine S Huang, Dietmar A Seiffert, Robert Rehfuss, Ruth R Wexler, Patrick Y S Lam
• Journal: Journal of medicinal chemistry (J Med Chem) Vol. 57 Issue 14 Pg. 6150-64 (Jul 24 2014) ISSN: 1520-4804 [Electronic] United States
• PMID: 24931384 (Publication Type: Journal Article)

Chemical References

• Indoles
• Platelet Aggregation Inhibitors
• Purinergic P2Y Receptor Antagonists
• Receptors, Purinergic P2Y1
• indoline

Topics

• Animals
• Blood Coagulation (drug effects)
• Dose-Response Relationship, Drug
• Drug Discovery
• Humans
• Indoles (chemistry, pharmacology)
• Mice
• Microsomes, Liver (chemistry, drug effects, metabolism)
• Molecular Structure
• Platelet Aggregation (drug effects)
• Platelet Aggregation Inhibitors (chemical synthesis, chemistry, pharmacology)
• Purinergic P2Y Receptor Antagonists (chemical synthesis, chemistry, pharmacology)
• Rabbits
• Rats
• Receptors, Purinergic P2Y1 (metabolism)
• Structure-Activity Relationship
• Thrombosis (drug therapy)